Expression of PI3K-AKT-mTOR signaling pathway in gastric cancer

Background: The PI3K/AKT/m TOR pathway is activated in gastric cancer (GC). This may be an appropriate target for GC therapy. Such therapy involve inhibiting cell proliferation, enhancing apoptosis, and restoring the sensitivity of cells to chemotherapy. Aim: To study expression PI3K/AKT/mTOR Egyptian patients with GC. Methods: Enrolled Patients were divided into 2 groups, group 1 included 23 lymph node metastatic (LNM) (GC) 10 non-metastatic Liver renal biochemical tests, CBC, H. pylori testing, CEA, CA19-9 & radiological work up done. Upper Gastrointestinal endoscopy was done diagnose site, size morphology take biopsy from suspicious lesion, adjacent mucosa all parts stomach. had received surgical resection when appropriate. harvested tumor tissue processed histopathology as well Immunohistochemical staining (IHC) detection PI3K/AKT/mTOR. IHC score mTOR, AKT PI3K (ranging 0 12) calculated follows: Grade stain intensity × coloration rate. A ≥4 considered positive. Results: mTOR positive 54.5%, 72.7% 36.4% cases. There significantly higher (87%) than (40%), p=0.010. LNM (median 2.5), p=0.028. at cutoff value more 3 a statistically significant discriminator between GC, AUC=0.743, p=.014, sensitivity, 87% specificity, 60%. Conclusion: discriminate LN